Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-Ad6-1 Phase 1 in Healthy Volunteers for COVID-19
NCT04839042Phase 1Completed
- Sponsor
- Moat Biotechnology
- Start
- Jun 2021
- Primary completion
- Mar 2025
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of SC-Ad6-1 in coronavirus disease 2019 (COVID-19) (18 arms), sponsored by Moat Biotechnology. Primary endpoints: Number of participants with solicited local and systemic adverse events, Incidence and severity of adverse events (AEs) and 1 more. Started Jun 2021; status: completed.
02
Drugs
SC-Ad6-1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04839042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839042.